Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Indivior Pharmaceuticals (INDV) Shares Repurchased (2024 - 2026)

Indivior Pharmaceuticals has reported Shares Repurchased over the past 3 years, most recently at $126.0 million for Q1 2026.

  • For Q1 2026, Shares Repurchased rose 1045.45% year-over-year to $126.0 million; the TTM value through Mar 2026 reached $126.0 million, down 14.86%, while the annual FY2025 figure was $11.0 million, 93.64% down from the prior year.
  • Shares Repurchased for Q1 2026 was $126.0 million at Indivior Pharmaceuticals, up from $11.0 million in the prior quarter.
  • Over five years, Shares Repurchased peaked at $126.0 million in Q1 2026 and troughed at $11.0 million in Q1 2025.
  • A 3-year average of $51.7 million and a median of $43.0 million in 2024 define the central range for Shares Repurchased.
  • Biggest five-year swings in Shares Repurchased: tumbled 69.44% in 2025 and later soared 1045.45% in 2026.
  • Year by year, Shares Repurchased stood at $50.0 million in 2024, then crashed by 78.0% to $11.0 million in 2025, then soared by 1045.45% to $126.0 million in 2026.
  • Business Quant data shows Shares Repurchased for INDV at $126.0 million in Q1 2026, $11.0 million in Q1 2025, and $50.0 million in Q4 2024.